Related Experiment Video

Updated: May 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and

R Leibowitz-Amit1, A M Joshua

  • 1Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON.

Current Oncology (Toronto, Ont.)
|January 29, 2013
PubMed

Insights

Significant advancements in understanding castration-resistant prostate cancer (CRPC) have led to new therapies targeting androgen receptor (AR) pathways. Novel drugs like abiraterone acetate and enzalutamide improve survival in metastatic CRPC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer progression involves castration-resistant states.
  • Castration-resistant prostate cancer (CRPC) often remains androgen receptor (AR)-dependent.
  • Understanding AR pathway dependence is crucial for CRPC treatment.

Purpose of the Study:

  • To review molecular mechanisms of CRPC and AR dependence.
  • To summarize clinical trials targeting hormonal pathways in metastatic CRPC.
  • To discuss resistance mechanisms and future research directions for novel hormonal agents.

Main Methods:

  • Literature review of molecular mechanisms in CRPC.
  • Summary of completed and ongoing clinical trials for metastatic CRPC.
  • Analysis of resistance mechanisms and future therapeutic strategies.

Main Results:

  • New drugs, abiraterone acetate and enzalutamide, prolong survival in metastatic CRPC.
  • Abiraterone acetate shows efficacy pre-chemotherapy.
  • Ongoing development of novel AR-targeting agents and heat shock protein inhibitors.

Conclusions:

  • Novel hormonal therapies targeting the AR pathway represent a significant advancement in CRPC treatment.
  • Understanding and overcoming resistance mechanisms is critical for future therapeutic development.
  • Further research on drug sequencing and combinations is needed to optimize patient outcomes.
Keywords:
ARN-509CYP17ODM-201Prostateabirateroneandrogenbicalutamidecastrationenzalutamidegaleteroneorteronel

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...